These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 38075247)
1. Kinetic analysis of oncolytic OrfV-induced innate and adaptive immune responses in a murine model of late-stage ovarian cancer. Minott JA; van Vloten JP; Yates JGE; Santry LA; Matuszewska K; Pereira M; Goens MM; Viloria-Petit AM; Wood GA; Karimi K; Petrik JJ; Bridle BW; Wootton SK Mol Ther Oncolytics; 2023 Dec; 31():100748. PubMed ID: 38075247 [TBL] [Abstract][Full Text] [Related]
2. Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer. van Vloten JP; Matuszewska K; Minow MAA; Minott JA; Santry LA; Pereira M; Stegelmeier AA; McAusland TM; Klafuric EM; Karimi K; Colasanti J; McFadden DG; Petrik JJ; Bridle BW; Wootton SK J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296558 [TBL] [Abstract][Full Text] [Related]
3. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. McGray AJR; Huang RY; Battaglia S; Eppolito C; Miliotto A; Stephenson KB; Lugade AA; Webster G; Lichty BD; Seshadri M; Kozbor D; Odunsi K J Immunother Cancer; 2019 Jul; 7(1):189. PubMed ID: 31315674 [TBL] [Abstract][Full Text] [Related]
4. The Role of Neutrophils in Oncolytic Orf Virus-Mediated Cancer Immunotherapy. Minott JA; van Vloten JP; Chan L; Mehrani Y; Bridle BW; Karimi K Cells; 2022 Sep; 11(18):. PubMed ID: 36139433 [TBL] [Abstract][Full Text] [Related]
5. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia. Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618 [TBL] [Abstract][Full Text] [Related]
6. The Combined Use of Orf Virus and PAK4 Inhibitor Exerts Anti-tumor Effect in Breast Cancer. Deng H; Xiao B; Huang Y; Weng K; Chen J; Li K; Wu H; Luo S; Hao W Front Microbiol; 2022; 13():845259. PubMed ID: 35401439 [TBL] [Abstract][Full Text] [Related]
7. Identification of in vitro and in vivo oncolytic effect in colorectal cancer cells by Orf virus strain NA1/11. Chen D; Wang R; Long M; Li W; Xiao B; Deng H; Weng K; Gong D; Liu F; Luo S; Hao W Oncol Rep; 2021 Feb; 45(2):535-546. PubMed ID: 33416161 [TBL] [Abstract][Full Text] [Related]
8. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade. Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694 [TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. Jennings VA; Ilett EJ; Scott KJ; West EJ; Vile R; Pandha H; Harrington K; Young A; Hall GD; Coffey M; Selby P; Errington-Mais F; Melcher AA Int J Cancer; 2014 Mar; 134(5):1091-101. PubMed ID: 23982804 [TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644 [TBL] [Abstract][Full Text] [Related]
11. Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity. Lin J; Sun S; Zhao K; Gao F; Wang R; Li Q; Zhou Y; Zhang J; Li Y; Wang X; Du L; Wang S; Li Z; Lu H; Lan Y; Song D; Guo W; Chen Y; Gao F; Zhao Y; Fan R; Guan J; He W Nat Commun; 2023 Jan; 14(1):224. PubMed ID: 36641456 [TBL] [Abstract][Full Text] [Related]
12. Orf Virus ORF120 Protein Positively Regulates the NF-κB Pathway by Interacting with G3BP1. Zhou Y; Guan J; Gao F; Li Z; Lan Y; Lu H; Song D; Lv L; Lv P; Xu M; Wang Z; He H; Zhao K; He W J Virol; 2021 Sep; 95(19):e0015321. PubMed ID: 34287041 [TBL] [Abstract][Full Text] [Related]
13. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer. Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156 [TBL] [Abstract][Full Text] [Related]
14. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation. Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846 [No Abstract] [Full Text] [Related]
15. Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines. Alluqmani N; Jirovec A; Taha Z; Varette O; Chen A; Serrano D; Maznyi G; Khan S; Forbes NE; Arulanandam R; Auer RC; Diallo JS Front Immunol; 2022; 13():1032356. PubMed ID: 36532027 [TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109 [TBL] [Abstract][Full Text] [Related]
17. Preclinical efficacy and involvement of mTOR signaling in the mechanism of Orf virus against nasopharyngeal carcinoma cells. Huang Y; Gong K; Chen J; Deng H; Weng K; Wu H; Li K; Xiao B; Luo S; Hao W Life Sci; 2022 Feb; 291():120297. PubMed ID: 35007565 [TBL] [Abstract][Full Text] [Related]
18. Oncolytic adenovirus decreases the proportion of TIM-3 Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929 [TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells. Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978 [TBL] [Abstract][Full Text] [Related]
20. Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. Bolyard C; Yoo JY; Wang PY; Saini U; Rath KS; Cripe TP; Zhang J; Selvendiran K; Kaur B Clin Cancer Res; 2014 Dec; 20(24):6479-94. PubMed ID: 25294909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]